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Introduction. Contrast media can cause acute renal failure by direct toxic effects on the tubular cells 
and kidney ischemia. Diabetics and hospitalized patients have a greater risk of developing contrast-
induced nephropathy than the general population.
Objective. The cost effectiveness of iso and low-osmolality contrast media was assessed in high risk 
outpatients.
Materials and methods. The analysis was based on a systematic literature review comparing the 
nephrotoxic effects of iso- to low-osmolality contrast media. Only direct costs were considered; these 
were obtained from the official tariff manual. Incremental cost-effectiveness ratios, efficiency curves 
and acceptability curves were calculated. Univariate sensitivity analyses were performed for costs and 
effects, as well as probabilistic analyses. Zero and 3% discounts were applied to results. The cost-
effectiveness threshold was equal to the per capita GDP per life-year gained.
Results. Alternatives with Iopamidol and Iodixanol are preferable to the others, because both reduce 
risk of contrast-induced nephropathy and are less costly. The incremental cost-effectiveness of the 
Iodixanol alternative compared to the Iopamidol alternative is US$ 14,660 per additional life year 
gained; this is more than twice the threshold. 
Conclusion. The low-osmolality contrast medium, Iopamidol, appears to be cost-effective when 
compared with Iohexol or other low-osmolality contrast media (Iopromide, Iobitridol, Iomeprol, Iopentol 
and Ioxilan) in contrast-induced nephropathy, high-risk outpatients. The choice of the iso-osmolality 
contrast medium, Iodixanol, depends on its cost per vial and on the willingness to pay.
Key words: contrast media; kidney tubular necrosis, acute; cost-benefit analysis.
Costo-efectividad de medios de contraste isoosmolales e hiposmolales en pacientes con alto 
riesgo de nefropatía inducida por medio de contraste
Introducción. Los medios de contraste pueden provocar falla renal aguda por toxicidad directa sobre 
las células tubulares e isquemia medular renal. Los pacientes diabéticos y los hospitalizados presentan 
mayor riesgo de desarrollar nefropatía inducida por medios de contraste que la población general.
Objetivo. Establecer el costo-efectividad de los medios de contraste isosmolales e hiposmolales en 
pacientes con alto riesgo.
Materiales and métodos. El análisis se basó en una revisión sistemática de la literatura científica, 
comparando los efectos nefrotóxicos de los medios isosmolales e hipoosmolales. Se consideraron sólo 
los costos directos, obtenidos del manual tarifario. Se calcularon las tasas del incremento del costo-
efectividad, las curvas de eficiencia y de aceptabilidad. Se hicieron análisis univariados de sensibilidad 
para costos y efectos, así como probabilísticos. Se aplicaron tasas de descuento de 0 y 3 % a los 
resultados. Se usó como umbral de costo-efectividad por año de vida ganado, el producto interno bruto 
per cápita.
Resultados. Las alternativas con Iopamidol y Iodixanol dominan a las demás porque reducen el riesgo 
de nefropatía inducida por contraste a un menor costo. La razón del incremento del costo-efectividad 
del iodixanol comparado con el iopamidol es de US$ 14.660 por año de vida ganado que más que 
duplica el umbral.
Conclusión. El medio de baja osmolalidad, iopamidol, parece ser costo-efectivo comparado con 
iohexol u otros medios hiposmolares (iopromide, iobitridol, iomeprol, iopentol y ioxilan), en pacientes 
con alto riesgo de nefropatía inducida por contraste. La elección del medio hiposmolar, depende de la 
disponibilidad a pagar o del costo por ampolleta.
Palabras clave: medios de contraste, necrosis tubular aguda, análisis costo-eficiencia.
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Contrast-induced nephropathy (CIN) is defined by 
the European Society of Urogenital Radiology as 
an increase in serum creatinine by more than 25% 
or 44 mmol/L (0.5 mg/dL) within 3 days after the 
intravascular administration of contrast medium, 
without an alternative etiology (1). CIN is one of the 
main etiological factors of acute kidney failure in 
hospitalized patients. It is also an important cause 
of morbidity, mortality, high cost and long hospital 
stays. Incidence of CIN in the general population is 
lower than 2% (2). Risk factors for CIN include pre-
existing renal impairment, diabetes, dehydration, 
allergies and advanced age. In patients with high 
risk of CIN, such as diabetics with kidney damage, 
CIN occurs in 12%-50% of the cases (3). CIN is 
the third most common cause of kidney failure in 
hospitalized patients, being the putative cause in 
12% of cases (4).
High-osmolality contrast media have more than 2-3 
times the osmolality of plasma, low osmolality media 
have up to 2-3 times the osmolality of plasma; iso-
osmolality contrast media have a similar osmolality 
to plasma. Low-osmolality contrast media include 
Gatoteridol, Iohexol, Ioversol, Metrizamide and 
Iopamidol; Iodixanol belongs to the iso-osmolality 
group.
Contrast media cause nephrotoxicity by direct 
toxicity upon the tubular cells and kidney ischemia. 
Meta analyses have found that the use of non-ionic 
low-osmolality media decreases CIN risk in high 
risk patients, compared to high-osmolality ionic 
media (5,6). For diabetic patients with medium to 
moderate kidney failure (i.e., with high risk of CIN), 
a recent randomized clinical trial found that an iso-
osmolality contrast media (Iodixanol) decreases 
CIN risk compared to a low-osmolality contrast 
media (Iohexol) (7).
Based on these results, iso-osmolality media may 
cause fewer kidney failure episodes than low-
osmolality media. However, media differ in other 
features, such as ionicity, viscocity and molecular 
size.  Each can contribute to differing risk profiles 
for kidney failure, even though each may have the 
same osmolality (8).
In addition to variability in nephrotoxic effects, 
contrast media vary in their costs. Herein, the cost 
effectiveness of iso and low-osmolality contrast 
media is assessed for outpatients with high CIN 
risk.
Materials and methods
In order to assess the cost-effectiveness of contrast 
media in outpatients with high CIN risk, a decision 
tree model was used (figure 1). The alternative 
media assessed were (1) iohexol, (2) iopamidol, 
(3) iodixanol, and (4) other low osmolality media 
(Iopromide, Iobitridol, Iomeprol, Ioxaglate, Iopentol 
and Ioxilan). Effectiveness was measured in life 
years gained--as QALYs (quality-adjusted life year) 
have not been calculated for this case for Colombia. 
The effects (death due to NIMC) are immediate, but 
if the patient survives, he/she is assumed to survive 
to full life expectancy. Hence, the time horizon is the 
expectancy of life—a period assumed to lie between 
the life expectancy at birth (74 years in Colombia) 
and 84. Life years gained were calculated as the life 
expectancy minus the average age of the patients 
(assumed to be 63 years). The results and costs 
were calculated with 0% and 3% discounts. The 
threshold for cost effectiveness was the Colombian 
per capita GDP, US $5,356.
Clinical data
Probabilities were extracted from a systematic 
review of the literature performed by the 
Department of Radiology and Diagnostic Images, 
Faculty of Medicine, Universidad Nacional de 
Colombia, following the instructions of the Method 
Group for Clinical Practice Guidelines (CPG 2010) 
(9) in the development of the CPG for the use of 
contrast media in radiologic procedures. From 
this revision, information was taken on CIN risk 
for each of the contrast media (8,10,11). Data on 
secondary mortality were extracted from published 
observational studies and economic analyses (12-
14). Data used in the model, as well as the sensitivity 
analyses intervals appear in table 1.
Cost data
The perspective was that of the third payer (costs 
incurred by Colombian National Health System). 
Only direct costs related to contrast media, and the 
handling of renal complications resulted from them, 
were taken into account (table 2). Prophylaxis costs 
were not included, although these costs do not alter 
the incremental cost-effectiveness ratio (ICER) as 
they were the same for both alternatives. Costs 
of contrast media were market prices; the cost of 
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Figure 1. Decision tree for economic evaluation of iso and low-osmolality contrast media
handling complications was calculated according 
to official rates in SOAT (SOAT is the Colombian 
tariff handbook for drugs and medical procedures). 
Costs were expressed in US dollars at official 
exchange rate of December 31, 2009 (2,044.23 
Col pesos per US dollar).
Analysis
ICER, efficiency curves, and acceptability curves 
were calculated, comparing each alternative to the 
Iopamidol strategy. Univariate sensitivity analyses 
were performed for costs and effects, as well as 
a probabilistic analysis with the distributions of the 
variables extracted of the literature.
Results
Results of the analyses appear in table 3 and 4. 
Alternatives with Iopamidol and Iodixanol were the 
preferred alternatives compared with iohexol or 
other low-osmolality contrast media, as they were 
less expensive and more effective in reducing CIN 
risk and gaining life years. With a 3% discount (table 
3), the cost of the iodixanol alternative compared 
to the iopamidol alternative was US $15,476 per 
additional avoided nephropathy and $14,660 for 
additional life-year gained (almost three times the 
threshold). With 0% discount (table 4) the ICER of 
Iodixanol compared to Iopamidol was $6,216.77, 
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which again was higher than the threshold. Without 
discount, Iopamidol still was the preferred outcome 
over Iohexol and other low osmolality media.
The efficiency frontier appears in figure 2. The 
Iopamidol and Iodixanol alternatives were on the 
efficiency line, whereas the others were above 
this line. Choice of preferred strategy depends on 
willingness to pay (WTP). The Iodixanol alternative 
was cost-effective for a WTP higher than US 
$14,660 per life-year gained.  This corresponds to a 
budget higher than US $455 per avoided additional 
CIN.  Iopamidol was considered cost-effective for a 
lower budget.
Univariate sensitivity analyses
In the one-way sensitivity analyses for clinical data, 
the main variables affecting results were as follows: 
the risk of CIN with iopamidol, hospitalization days, 
life expectancy and the probability of requirement 
of dialysis for patients with CIN. However, the only 
variable with an impact on decision was the risk of 
CIN with iopamidol: if it became higher than 0.11, 
this alternative would be dominated by Iodixanol.
In the one-way sensitivity analyses for costs, the 
variables with higher impact were the hospitalization 
costs and the price of the contrast media. Iopamidol 
became less cost-effective when price per 50 ml 
Table 2. Costs used in the economic evaluation of evaluations of iso and low-osmolality contrast media in CIN high-risk outpatients.
Variable Base (US $) Range (US $)
Iopamidol vial/50 ml* 26.6 13.3 39.9
Iohexol vial/50 ml* 21.5 10.7 32.2
Other low-osmolality vial/50 ml* 23.8 11.9 35.7
Iodixanol vial/50 ml* 52.7 26.3 79.0
Day of hospitalization in CCU 402.8 201.4 604.2
Day of hospitalization no CCU 100.4 50.2 150.6
Dialysis 151.2 75.6 226.8
Placement temporary venous catheter 149.9 74.9 224.8
Creatinine, BUN, electrolites and blood gas analysis 56.9 28.4 85.3
CCU: Critical Care Unit
BUN: Bllod Urea Nitrogen
*To calculate the average dose of contrast medium was used the formula: dose = 5ml*weight (kg) / serum creatinine. The calculations 
were made for a weight of 70 kg and a serum creatinine of 2 mg/dl.
Prices in 2009 US dollars
Table 1. Data used in the economic evaluation of evaluations of iso and low-osmolality contrast media in CIN high-risk outpatients. 
 Deterministic* Probabilistic** Reference
Variable Base Range Distribution Parameters  
Age (years) 63 50       70         Assumptions
Life expectancy (years) 74 74       84        Assumptions
Probability of ARF with Iohexol 0.21 0.18 0.23 β	 α=0.46;		β=1.79 (8, 10-11)
Probability of ARF with Iodixanol 0.09 0.08 0.11 β	 α=0.2;		 β=1.91 (8, 10-11)
Probability of ARF with Iopamidol 0.1 0.08 0.12 β	 α=0.21;		β=1.9 (8, 10-11)
Probability of ARF whith Other low 0.18 0.16 0.21 β	 α=	0.41;		β=1.82 (8, 10-11)
-osmolality media
Mortality by ARF 0.16 0.13 0.18 β	 α=0.34;		β=1.84 (12)
Mortality by no ARF 0.05 0.04 0.07 β	 α=0.11;		β=1.95 (12)
Probability of Dialysis  0.36 0.22 0.62 β	 α=0.92;		β=1.64 (13-14)
Probability of need CCU  0.29 0.15 0.44 β	 α=0.7;		 β=1.71 (13-14)
Hospitalization days no nephropathy 2          (13-14)
Hospitalization	days	nephropathy		 4	 2	 8	 LogNormal	 μ=1.38;		σ=0.18	 (13-14)
without dialysis 
Hospitalization	days	nephropathy	 6	 5	 17	 LogNormal	 μ=1.79;		σ=0.4	 (13-14)
with dialysis
*Ranges used in deterministic sensitivity analysis
**Distributions used in probabilistic sensitivity analysis
ARF: Acute Renal Failure
CCU: Critical Care Unit
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Table 3. Costs, LYsG, cost effectiveness rate and incremental cost effectiveness rate for different contrast media in CIN high-risk 
outpatients (3% discount)
Strategy Costs (US $) Incremental  Effectiveness   Incremental  C/E ICER   
  cost (US $) (LYsG) effectiveness (LYsG) (US $/ LYsG) (US $/ LYsG)
Iopamidol 381.6  71.793  5.31 
Iodixanol 454.9 73.3 71.798 0,005 6.33 14,660
Other- low osmolality 458.7 3.8 71.712 -0,086 6.39 (Dominated)
Iohexol 472.5 13.8 71.692 -0,02 6.59 (Dominated)
Table 4. Costs, LYsG, cost effectiveness rate and incremental cost effectiveness rate for different contrast media in CIN high-risk 
outpatients (0% discount) 0% discount
Strategy Costs (US $) Incremental  Effectiveness   Incremental  C/E ICER   
  cost (US $) ss (LYsG) effectiveness (LYsG) (US $/ LYsG) (US $/ LYsG)
Iopamidol 388.3  72.473  5.31 
Iodixanol 462.9 74.6 72.485 0.012 6.33 6,216.77
Other- low osmolality 466.7 3.8 72.266 -0.219 6.39 (Dominated)
Iohexol 480.8 14.1 72.215 -0.051 6.59 (Dominated)
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Figure 2. Efficiency frontier for different strategies in economic evaluation of iso and low-osmolality contrast media
vial was higher than US $51; Iodixanol became 
cost-effective when the price for 50 ml vial was 
lower than $28. Hospitalization days affected total 
costs, but not the decision. Iohexol and other low 
osmolality media were preferable at any price. Life 
expectancy does not affect the results.
Probabilistic sensitivity analysis
As can be seen in the acceptability curve (figure 3), 
the iopamidol alternative is more likely to be cost-
effective, followed by the iodixanol alternative, within 
the willingness-to-pay range of US $0 to $11,740.
Discussion
The economic burden of CIN is important and the 
adoption of targeted interventions reducing CIN 
incidence are relevant. Patients who develop CIN 
are more likely to experience adverse events, to 
undergo prolonged dialysis, to have longer hospital 
and intensive care unit stays and to have higher 
mortality rates. One study has estimated that the 
average in-hospital cost of CIN is higher than US 
$10,345 and the 1-year cost of treating a patient 
with CIN is US $11,812 (15). 
Several strategies have been developed for 
reducing the risk of CIN, including the prophylactic 
use of N-acetylcysteine, theophylline, sodium 
bicarbonate, HMG Co-A reductase inhibitors, 
ascorbic acid, fenoldopam, diuretics, and saline or 
half saline media (16-18). Moreover, new techno-
logical developments have resulted in progressive 
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improvement in the safety and tolerability of 
iodinated contrast media, especially for patients at 
risk for contrast-associated complications. Clinical 
trials have demonstrated an improved safety profile 
for low-osmolality contrast media compared with 
high-osmolality contrast media in terms of CIN risk 
(6,19,20).
In the Colombian setting, the alternative with 
Iopamidol was cost-effective in the prevention of 
contrast-induced acute nephropathy, because 
Iopamidol has lower cost and higher effectiveness 
when compared with Iohexol and other low-
osmolality contrast media strategies. On the other 
hand, the alternative with Iodixanol is cost-effective 
if the budget per patient was higher than US $455 
or the cost of the 50 ml vial lower than US $28. 
Also, Iodixanol became cost effective when a 
higher threshold was used, i.e., three times the per 
capita GDP.
The dependence of the cost-effectiveness of 
Iodixanol on willingness-to-pay (WTP) in a 
developing country was in agreement with the 
result for developed countries, which have 
higher WTP. An economic analysis conducted 
for 17 European hospitals showed that Iodixanol 
appeared to be cost-effective when compared with 
Iohexol in diabetic patients with renal impairment 
undergoing angiography (21), although this study 
measured effectiveness in terms of adverse drug 
reactions avoided. No previous studies of the cost-
effectiveness of contrast media in the prevention 
of CIN in a developing country setting were found 
in a the review of the literature. Only one study 
evaluated the cost-effectiveness of contrast media 
in a European country in CT examination (22).  The 
authors found that the net differential cost between 
universal and selective use of low-osmolality 
contrast medium was US $43.90 per patient when 
all outcomes were considered. The selective 
alternative (low-osmolality in only CIN high risk 
patients) was safe and effective, and resulted in a 
substantial reduction in costs.
A limitation of the present analysis was that 
the difference in the probability of nephropathy 
between Iopamidol and Iodixanol were very small 
and not statistically significant.  Therefore, the 
incremental effectiveness of Iopamidol strategy 
was also small, and hence, the interpretation of 
the ICER is subject to discussion. However, the 
difference with the other two alternatives was 
statistically significant, and the analysis performed 
permitted their assessment.  If the focus was only 
on Iopamidol and Iodixanol, and the probability 
of nephropathy considered to be equal, a cost 
minimization exercise is recommended. If the 
information provided here were to be interpreted in 
this way, Iopamidol remains to be preferred over 
Iodixanol, since the total costs of its use are lower.
Another approach is to focus on a surrogate (cases 
of CIN avoided), rather than on life years. CIN is 
recognized to have possible long-term consequences, 
even leading to increased morbidity and mortality 
(3,23); however, the information on the cost of 
avoiding an additional case of CIN may be of greater 
importance in some contexts. Figure 3 shows that 
when the acceptability curve was calculated in terms 
of avoided CIN, the results became consistent. This 
information is useful if the preferred a cost benefit 
analysis focused on the monetary costs of treating a 
CIN. In this case (given that the cost of treating a CIN 
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Figure 3. Acceptability curve of probabilistic analysis in economic evaluation of iso and low-osmolality contrast media with a 
surrogate outcome
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case is approximately US $11,000), figure 3 indicates 
Iopamidol as the better alternative on a cost benefit 
basis. These comparisons suggest that the results 
are robust to different foci and preferences regarding 
the type of economic analysis.
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